Table 3 Frequency results for AC study genotype and allelotype

From: Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide

 

Genotype frequency, n (%)

Allele frequency, n (%)

 

wt/wt

wt/v

v/v

wt

v

ABCB1 ex12 (C1236T)

66 (29)

104 (45)

60 (26)

236 (51)

224 (49)

ABCB1 ex21 (G2677T/A)

61 (27)

wt/vT=98 (43)

vT/vT=61 (27)

224 (49)

VT=225 (49)

  

wt/vA=4 (2)

vA/vA=1 (0.4)

 

vA=11 (2)

   

vT/vA=5 (2)

  

ABCB1 ex26 (C3435T)

41 (18)

112 (49)

77 (34)

194 (42)

266 (58)

SLC22A16 ex2 (A146G)

147 (64)

71 (31)

12 (5)

365 (79)

95 (21)

SLC22A16 ex2 (T312C)

147 (64)

71 (31)

12 (5)

365 (79)

95 (21)

SLC22A16 ex4 (T755C)

193 (84)

36 (16)

1 (0.4)

422 (92)

38 (8)

SLC22A16 ex5 (T1226C)

130 (57)

84 (37)

16 (7)

344 (75)

116 (25)

CYP2B6*2 (C64T)

219 (95)

11 (5)

0 (0)

449 (98)

11 (2)

CYP2B6*8 (A415G)

228 (99)

2 (1)

0 (0)

458 (99.6)

2 (0.4)

CYP2B6*9 (G516T)

110 (48)

103 (45)

17 (7)

323 (70)

137 (30)

CYP2B6*3 (C777A)

230 (100)

0 (0)

0 (0)

460 (100)

0 (0)

CYP2B6*4 (A785G)

125 (54)

87 (38)

18 (8)

337 (73)

123 (27)

CYP2B6*5 (C1459T)

165 (72)

60 (26)

5 (2)

390 (85)

70 (15)

CYP2C9*2 (C430T)

165 (72)

58 (25)

7 (3)

388 (84)

72 (16)

CYP2C9*3 (A1075C)

197 (86)

33 (14)

0 (0)

427 (93)

33 (227)

CYP3A5*3 (A6986G)

1 (0.4)

32 (14)

197 (86)

34 (7)

426 (93)

CYP2C19*2 (G681A)

163 (71)

64 (28)

3 (1)

390 (85)

70 (15)

  1. Abbreviations: AC=doxorubicin and cyclophosphamide; wt=wild-type alllele; v=variant allele.
Back to article page